BioAge Labs has initiated a Phase 2 trial of BGE-102, an oral NLRP3 inhibitor, in adults with diabetic macular edema—a leading cause of vision loss in working-age populations. The trial will evaluate the compound as both monotherapy and as an adjunct to standard anti-VEGF therapy, with results expected in 2027.
Key Points
- NLRP3 inhibition targets inflammatory pathway central to diabetic retinal disease
- Oral formulation offers systemic accessibility versus current intravitreal injection standard
- Trial design tests both standalone and combination efficacy across three treatment arms
Longevity Analysis
Diabetic macular edema represents a convergence of metabolic dysfunction, inflammatory dysregulation, and vascular compromise—conditions that compromise both visual function and broader systemic aging. An orally available NLRP3 inhibitor addresses a foundational mechanism rather than symptom management alone. The dual approach—testing as monotherapy and as adjunctive therapy—provides clinical evidence for whether downstream inflammation can be controlled independently or requires concurrent suppression of angiogenic signaling. Success here would establish a precedent for systemic anti-inflammatory intervention in conditions previously managed through localized delivery, potentially reshaping how retinal and other age-related diseases are approached.
Original published by LT Wire.